Dasatinib

Name: Dasatinib
Brand: Selleck Chemicals
SKU: S1021
Rating: 5 (386 reviews)

For research use only.

Catalog No.S1021 Synonyms: BMS-354825

386 publications

CAS No. 302962-49-8

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.

Selleck's Dasatinib has been cited by 386 publications

Nature, 2020, 10.1038/s41586-020-2884-6

PubMed: 33149299 ( click the link to review the publication )

Science, 2020, 370(6513)eabc2754

PubMed: 33004676 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 10;S1934-5909(20)30144-2

PubMed: 32413332 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell, 2012, 21;151(7):1457-73.

PubMed: 23245941 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Blood, 2020, 8 pii: blood

PubMed: 32270193 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(4):1879-1895

PubMed: 31874105 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5842

PubMed: 33203880 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )
Neuro Oncol, 2020, 15;22(4):493-504

PubMed: 31883012 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, 30 pii: canres

PubMed: 32354737 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):3951-3963 e4

PubMed: 32209458 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

Oncogene, 2020, 39(20):3980-3996

PubMed: 32238881 ( click the link to review the publication )

Oncogene, 2020, 39(2):308-321

PubMed: 31477830 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 39(20):4045-4060

PubMed: 32214198 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 25;12(5)

PubMed: 32344828 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2730

PubMed: 32977582 ( click the link to review the publication )

Cancers (Basel), 2020, 31;12(4) pii: E841

PubMed: 32244515 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3869

PubMed: 33371412 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Breast Cancer Res, 2020, 15;22(1):37

PubMed: 32295603 ( click the link to review the publication )

Cell Death Discov, 2020, 15;6:36

PubMed: 32435511 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )
FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Br J Haematol, 2020, 10.1111/bjh.17139

PubMed: 33216963 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):270

PubMed: 32631432 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Microb Cell Fact, 2020, 20;19(1):74

PubMed: 32197603 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.14980

PubMed: 32032474 ( click the link to review the publication )

Biochem Pharmacol, 2020, 30;177:113941

PubMed: 32240650 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30604-3

PubMed: 33333074 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9276

PubMed: 33291786 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):20343

PubMed: 33230163 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16616

PubMed: 33024173 ( click the link to review the publication )

Sci Rep, 2020, 6;10(1):4211

PubMed: 32144278 ( click the link to review the publication )

Am J Pathol, 2020, S0002-9440(20)30550-2

PubMed: 33307038 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015489

PubMed: 33037073 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 179(2):337-347

PubMed: 31655920 ( click the link to review the publication )

Cell Signal, 2020, 70:109574

PubMed: 32084531 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 9

PubMed: 32268657 ( click the link to review the publication )
SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Blood Adv, 2020, 4(24):6106-6116

PubMed: 33351104 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31704808 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):145-154

PubMed: 32565942 ( click the link to review the publication )

J Clin Invest, 2020, 133310

PubMed: 32603316 ( click the link to review the publication )

Genome Biol, 2020, 21(1):174

PubMed: 32669109 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):139

PubMed: 32792487 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3416

PubMed: 32651372 ( click the link to review the publication )

Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )
Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(8):e8849

PubMed: 31464373 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(29):5805-5816

PubMed: 31235784 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1945

PubMed: 31817360 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

J Clin Med, 2019, 8(4)E455

PubMed: 30987403 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

Pharmacol Res, 2019, 147:104357

PubMed: 31356863 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )
Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17104

PubMed: 31745115 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

J Acquir Immune Defic Syndr, 2019, 82(4):407-415

PubMed: 31658184 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Exp Hematol, 2019, 77:36-40.e2

PubMed: 31493432 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):4449-4456

PubMed: 31611954 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31405946 ( click the link to review the publication )

Oncotarget, 2019, 10(31):2930-2946

PubMed: 31105876 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

J Extracell Vesicles, 2019, 9(1):1698889

PubMed: 31853340 ( click the link to review the publication )
Cancer Immunol Res, 2019, 7(9):1523-1534

PubMed: 31266784 ( click the link to review the publication )

Nat Neurosci, 2019, 22(5):719-728

PubMed: 30936558 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Am J Hum Genet, 2018, 103(6):976-983

PubMed: 30449416 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3607-3618

PubMed: 30257219 ( click the link to review the publication )

Cell Rep, 2018, 25(13):3674-3692.e10

PubMed: 30590041 ( click the link to review the publication )

Elife, 2018, 7e33304

PubMed: 30231971 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(38):5221-5232

PubMed: 29849118 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Sci Signal, 2018, 11(539)

PubMed: 30018082 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Front Immunol, 2018, 9:8

PubMed: 29403492 ( click the link to review the publication )
Front Immunol, 2018, 9:2033

PubMed: 30283437 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Oral Oncol, 2018, 78:56-63

PubMed: 29496059 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

J Cell Sci, 2018, 131(22)jcs221788

PubMed: 30404826 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):584

PubMed: 29330550 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1081

PubMed: 30319416 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cell Biol Int, 2018,

PubMed: 29885023 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6831-6838

PubMed: 29731862 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

J Pharmacokinet Pharmacodyn, 2018, 45(3):401-418

PubMed: 29446053 ( click the link to review the publication )

Oncotarget, 2018, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )
Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Leukemia, 2017, 31(5):1253-1254

PubMed: 28465516 ( click the link to review the publication )

Cancer Res, 2017,

PubMed: 27821486 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Int J Cancer, 2017, 140(5):1173-1185

PubMed: 27798955 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28638122 ( click the link to review the publication )
J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Front Mol Neurosci, 2017, 10:418

PubMed: 29326548 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 28945796 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Exp Ther Med, 2017,

PubMed: 28810597 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 8(27):43662-43677

PubMed: 28599273 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

Hepatology, 2017, 66(6):1934-1951

PubMed: 28714104 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Blood Adv, 2017, 1(26):2610-2623

PubMed: 29296914 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )
Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

EMBO Mol Med, 2016, 1;8(2):105-16

PubMed: 26758680 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Sci Signal, 2016, 9(456):ra116

PubMed: 27899526 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

Oncoimmunology, 2016, 5(12):e1240858

PubMed: 28123877 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1472-84

PubMed: 27364904 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(5):819-29

PubMed: 26883271 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Psychoneuroendocrinology, 2016, 66:138-49

PubMed: 26803529 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1862(11):2158-2167

PubMed: 27565738 ( click the link to review the publication )

Sci Rep, 2016, 6:26252

PubMed: 27188220 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )
BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164895

PubMed: 27768734 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45916-45925

PubMed: 27322141 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27602951 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27756880 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27687593 ( click the link to review the publication )

J Gen Virol, 2016, 97(5):1134-1144

PubMed: 26879209 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(17):24483-94

PubMed: 27016416 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2015, 35(11):2326-35

PubMed: 26359510 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(15):4296-305

PubMed: 25948553 ( click the link to review the publication )
ACS Chem Biol, 2015, 10(1):262-8

PubMed: 25248068 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2015, 56(9):5457-64

PubMed: 26284551 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Exp Hematol, 2015,

PubMed: 25641047 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015, 6(4):1967-80

PubMed: 25596742 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 80:56-65

PubMed: 26296860 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(36):38854-65

PubMed: 26513174 ( click the link to review the publication )
J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Oncogene, 2014,

PubMed: 23318431 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1005

PubMed: 24434513 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Stem Cells, 2014, 32(9):2324-37

PubMed: 24806995 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 24196445 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )
Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Pharmacogenet Genomics, 2014, 24(1):52-61

PubMed: 24322003 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Proteomics, 2013, 13(23-24):3554-62

PubMed: 24167056 ( click the link to review the publication )

Cell Adh Migr, 2013, 7(4):362-9

PubMed: 23751956 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )
Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Oncotarget, 2012, 3(12):1557-65

PubMed: 23238683 ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )
Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	NWrXb\|FXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUnqUJpJPzJiaB?=	NFnVPFZFVVOR	NYTYW5FFUUN3ME2wMlAxODB5IN88US=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl3NkC4NEc,OTd7NU[wPFA9N2F-
K562	NWm1XpF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3jVSFczKGh?	M4SyeGROW09?	MVrJR\|UxRTBwMECxJO69VQ>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl3NkC4NEc,OTd7NU[wPFA9N2F-
M07e	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVfPO5h2PzJiaB?=	NEKw[\|NFVVOR	MonaTWM2OD1yLkCwNVIh\|ryP	NVzxN\|A5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5OVYxQDBpPkG3PVU3ODhyPD;hQi=>
ALL3	Mkn1R5l1d3SxeHnjJGF{e2G7	MXywMlHPxE1?	M3nkU\|czKGh?	MVPEUXNQ	Mn;OTWM2OD1yLkCwNFQh\|ryP	M3fRSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEi5OVQxLz5zOUi4PVU1ODxxYU6=
CML	NWHxb5pMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWeyNEBucW5?	NIPMTppFVVOR	M3PoeGlEPTB;MD6wNFEh\|ryP	M2HNdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkG5NFE3Lz5zOUKxPVAyPjxxYU6=
BA/F3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlHDO\|IhcA>?	NEHne5BFVVOR	M3vaSmlEPTB;Nj61PFkh\|ryP	NIDxOXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C4PFY1PCd-MkOwPFg3PDR:L3G+
BA/F3	M{ftSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MojaO\|IhcA>?	NV;nSG9YTE2VTx?=	MVvJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?=	MkfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyOEi2OFQoRjJ\|MEi4OlQ1RC:jPh?=
BA/F3	NFT0OVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2TSVFczKGh?	NXjpZZJHTE2VTx?=	MlnGTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>?	NVX0W20yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwPFg3PDRpPkKzNFg5PjR2PD;hQi=>
BA/F3	M4\1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX23bmxZPzJiaB?=	MW\EUXNQ	MXPJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1?	NGWySpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C4PFY1PCd-MkOwPFg3PDR:L3G+
BA/F3	NVzIVGhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlnOO\|IhcA>?	NIC0XnRFVVOR	MXrJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>?	NVf1SpFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	NHvB[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1;TelczKGh?	NWq2VpM{TE2VTx?=	M{mzNGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz\|ryP	MnvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3NFMoRjJ\|M{CxO\|A{RC:jPh?=
BA/F3	NYj6Um44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYW3NkBp	NIm3fXlFVVOR	M2rCcmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy\|ryP	MojUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3NFMoRjJ\|M{CxO\|A{RC:jPh?=
BA/F3	MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYfnbYEzPzJiaB?=	NHXycZlFVVOR	Mn7OTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>?	NYr3PXdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	NVXiTHBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWi5XW41PzJiaB?=	MkHwSG1UVw>?	NGT4T\|RKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFAyO87:TR?=	NG\qeVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVcxOyd-MkOzNFE4ODN:L3G+
BA/F3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4rEd\|czKGh?	Mn7aSG1UVw>?	NYHIUYF[UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1?	MkPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3NFMoRjJ\|M{CxO\|A{RC:jPh?=
BA/F3	Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXG3NkBp	NIrPVpZFVVOR	NH7CV4ZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFAzO87:TR?=	M2joXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|A{Lz5{M{OwNVcxOzxxYU6=
BA/F3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGLUSYY4OiCq	NUfkXJM1TE2VTx?=	MnTsTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB\|LkdOwG0>	M3r0RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|A{Lz5{M{OwNVcxOzxxYU6=
BA/F3	M2fyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2PSb\|czKGh?	M3XnbWROW09?	M3i4Nmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFIvPc7:TR?=	M2Hx[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|A{Lz5{M{OwNVcxOzxxYU6=
T cell	MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXvwV2t1PzJiaB?=	NITk[YZFVVOR	NF61RlNKdmirYnn0d{BidnSrIFPEN{0h[W6mIHHueIkhS0R{OD3pcoR2[2WmIGSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwN:69VQ>?	M4P2N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUW0OVEzLz5zN{G1OFUyOjxxYU6=
WiDr	MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MY[3NkBp	NX;ZXHBQTE2VTx?=	MX3JR\|UxRTBwMEWyJO69VQ>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZzNUWxNkc,OTV4MUW1NVI9N2F-
PC3	NHPXUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWf2TYM6PzJiaB?=	M{TYXWROW09?	NX\OW2VEUUN3ME2wMlAxQTRizszN	MmTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4MUW1NVIoRjF3NkG1OVEzRC:jPh?=
MDA-MB-231	M2PRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEfZZVk4OiCq	Ml22SG1UVw>?	MYPJR\|UxRTBwMEGyJO69VQ>?	NIXYd\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOid-MUW2NVU2OTJ:L3G+
Hs578T	MlTpR5l1d3SxeHnjJGF{e2G7		MVO3NkBp	MVjEUXNQ	NWnL[Jp4T0l3ME2wMlA{KM7:TR?=	NXK2S\|RFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
HMEC	MmfFR5l1d3SxeHnjJGF{e2G7		MVy3NkBp	NW\ESZdrTE2VTx?=	NUDzdZp2T0l3ME2xMlgh\|ryP	NWDCOpRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
DU145	MWfDfZRwfG:6aXOgRZN{[Xl?		NYGzenRiPzJiaB?=	NWrVXZpvTE2VTx?=	NGjzUXRIUTVyPUCuNVYh\|ryP	NEnTS3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
U251	NYD2Z2kyS3m2b4TvfIlkKEG\|c3H5		MoHyO\|IhcA>?	M1KzcWROW09?	NHvUWJdIUTVyPUKuPFEh\|ryP	NXnhUJpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
NCI60	NIDMTWREgXSxdH;4bYMhSXO\|YYm=		NUf4UVE{PzJiaB?=	NVLhfXVCTE2VTx?=	NHHvclhIUTVyPUWuO{DPxE1?	NFT0dWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
MALME-3M	MkPHR5l1d3SxeHnjJGF{e2G7		NWjEXGN{PzJiaB?=	NFvhXnBFVVOR	NGKxdVlIUTVyPU[uOlEh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
KM12	Mn;YR5l1d3SxeHnjJGF{e2G7		NWDrNXdqPzJiaB?=	M2nZSWROW09?	MWrHTVUxRTdwNESg{txO	M3;OdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
SW620	NFfXUlVEgXSxdH;4bYMhSXO\|YYm=		NX\j[GI1PzJiaB?=	M4Lkb2ROW09?	MmHMS2k2OD16LkSzJO69VQ>?	M3fDWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
RXF 393NL	MYnDfZRwfG:6aXOgRZN{[Xl?		M4O5U\|Qh\GG7cx?=	NV;zZYtwTE2VTx?=	NWHlU5A6UUN3ME2wMlAzOTdizszN	NULIe5VQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVMxPzRpPkKzNlU{ODd2PD;hQi=>
LXFA 983L	M4jVfWN6fG:2b4jpZ{BCe3OjeR?=		NGr4V\|U1KGSjeYO=	MUfEUXNQ	NEDoU4xKSzVyPUCuNFU3PSEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3M{C3OEc,OjN{NUOwO\|Q9N2F-
PRXF DU145	MlTrR5l1d3SxeHnjJGF{e2G7		NIGxSGg1KGSjeYO=	MoHPSG1UVw>?	MUDJR\|UxRTBwME[yN{DPxE1?	NX;lb3BHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVMxPzRpPkKzNlU{ODd2PD;hQi=>
PAXF 1657L	MXzDfZRwfG:6aXOgRZN{[Xl?		NYfTepdUPCCmYYnz	Mlu1SG1UVw>?	MVHJR\|UxRTBwMUKxJO69VQ>?	NH[0WWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1N\|A4PCd-MkOyOVMxPzR:L3G+
CXF 1103L	Mn\0R5l1d3SxeHnjJGF{e2G7		NUDTV3NmPCCmYYnz	Mny3SG1UVw>?	Mnu5TWM2OD12LkO2JO69VQ>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3M{C3OEc,OjN{NUOwO\|Q9N2F-
GXF251L	NEW1cWxEgXSxdH;4bYMhSXO\|YYm=		M{XnXlQh\GG7cx?=	NVPB[Jd1TE2VTx?=	MnHSTWM2OD1{LkK1JO69VQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3M{C3OEc,OjN{NUOwO\|Q9N2F-
NCI-H23	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGLwOJA4OiCq	MVvEUXNQ	NXy3R5VtUUN3ME2yMlI4KM7:TR?=	NXXx[nBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NlExOjBpPkKzOVIyODJyPD;hQi=>
HCT116	NWHwepdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUW3NkBp	NGLyfmdFVVOR	NH\XNGpKSzVyPUKuN{DPxE1?	NV\BfVNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NlExOjBpPkKzOVIyODJyPD;hQi=>
MCF7	NIn4bYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnT0O\|IhcA>?	MUXEUXNQ	NF7YdYdKSzVyPUKuOVch\|ryP	M1X3NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUKxNFIxLz5{M{WyNVAzODxxYU6=
NCI-H460	M4q2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{jORVczKGh?	NHK0bmxFVVOR	MUnJR\|UxRThwOUmg{txO	M3jSVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUKxNFIxLz5{M{WyNVAzODxxYU6=
DLD1	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWW0TYFqPzJiaB?=	MXvEUXNQ	NFjXTJJKSzVyPUSuOkDPxE1?	M33tSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[3PVYxLz5{M{W2O\|k3ODxxYU6=
NCI-H661	NEjyc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1j5OlczKGh?	NIXkWGRFVVOR	MYjJR\|UxRTdwODFOwG0>	NFvG[289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2O\|k3OCd-MkO1Olc6PjB:L3G+
A549	NX2wR4pUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NITmSGg4OiCq	MYfEUXNQ	NEnwXZZKSzVyPUiuNkDPxE1?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4N{m2NEc,OjN3Nke5OlA9N2F-
U937	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIP3TZU4OiCq	NITS[opFVVOR	NVr2Wml{UUN3ME2xNk4zKM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4N{m2NEc,OjN3Nke5OlA9N2F-
HEK293	M4[4d2Z2dmO2aX;uJGF{e2G7	Ml7wNVDDqM7:TR?=		MVHEUXNQ	NYDlXHB2UW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0>	M2rRVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewOlExLz5{Mke3NFYyODxxYU6=
HUVEC	NXnhdmtST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\QfGYxNjF3wrFOwG0>	MmXyO\|IhcA>?	MoHVSG1UVw>?	NUfkWGJGUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO	NUHlUJpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVM6QTNpPkKyPFU{QTl\|PD;hQi=>
HUVEC	NV\iVXVXTnWwY4Tpc44hSXO\|YYm=	NUH4e3l3OTYEoN88US=>	Mke5O\|IhcA>?	MYDEUXNQ	NUjkVZQ3UW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1?	NVXrNVFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVM6QTNpPkKyPFU{QTl\|PD;hQi=>
Plasmodium falciparum	NI\KdWtHfW6ldHnvckBCe3OjeR?=	MkToNVDDqM7:TR?=	NV[3eYdLOTVibXnu	NHTkO4pFVVOR	NULmNVJxUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4\|ryP	NU\rTGxqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVA{OzBpPkK0OVUxOzNyPD;hQi=>
PC3	NWDiT4RSTnWwY4Tpc44hSXO\|YYm=	MnfPNE4yKM7:TR?=	M{LWdFUhcA>?	MX7EUXNQ	Mn7CTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P	NF2xNm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS2Nlk4PSd-MUm0OlI6PzV:L3G+
DU145	MonYSpVv[3Srb36gRZN{[Xl?	MonONE4yKM7:TR?=	MmW4OUBp	MV7EUXNQ	NED0TmRKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW\|aX;uJIF1KDFyMDDuUS=>	M2m0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NE[yPVc2Lz5zOUS2Nlk4PTxxYU6=
PC3	NG\TfnJMcW6jc3WgRZN{[Xl?	MVWwMlEh\|ryP	MUG1JIg>	NUO2NJJITE2VTx?=	M1fZ[GlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2=	NXux[\|ZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OlI6PzVpPkG5OFYzQTd3PD;hQi=>
DU145	NEC2S29McW6jc3WgRZN{[Xl?	NXnBZmRXOC5zIN88US=>	Ml[1OUBp	M1fwPGROW09?	MkGyTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N	M2G0e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NE[yPVc2Lz5zOUS2Nlk4PTxxYU6=
PC3	MUfLbY5ie2ViQYPzZZk>	NHf6bJMxNjFizszN	NYjJSYVbPSCq	NF7VblZFVVOR	MlLPTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR4Mkm3OUc,OTl2NkK5O\|U9N2F-
DU145	M2OxSmtqdmG\|ZTDBd5NigQ>?	NXfJNJh1OC5zIN88US=>	NUfiUnA1PSCq	Mle2SG1UVw>?	NGLGXlFKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?=	NUfadZBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OlI6PzVpPkG5OFYzQTd3PD;hQi=>
Huh7	NFHmfndCdnSrdnnyZYwhSXO\|YYm=	NGG1XmwzNjVizszN	NI\GN3Y1KGSjeYO=	MV3EUXNQ	MWHJcohq[mm2czD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1?	MmDEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC2O\|YoRjF5M{[wOlc3RC:jPh?=
C6/36	NEK3dnNCdnSrdnnyZYwhSXO\|YYm=	NFvDTVkzNjVizszN	MlvBOEBl[Xm\|	MXnEUXNQ	MXjJcohq[mm2czD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO	M3zuVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
U937	MUPGeY5kfGmxbjDBd5NigQ>?	NULFdHNrOSEQvF2=	MYSxJIg>	MVTEUXNQ	NVnrfW5LWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N\|ch[2WubIO=	NVPnZ25PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PFQxQTlpPkG3Olg1ODl7PD;hQi=>
U937	NGrpe2lHfW6ldHnvckBCe3OjeR?=	MlLTNUDPxE1?	NXKwOmhiOSCq	Mk\ySG1UVw>?	NYnXOpVZWmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN?	M3PG[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nki0NFk6Lz5zN{[4OFA6QTxxYU6=
murine mast cell	NUD3OYJwTnWwY4Tpc44hSXO\|YYm=	MUKxJO69VQ>?	MnT1NlQhcA>?	MlzmSG1UVw>?	NWW2WGFQUW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC\|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W\|ZTDtZZN1KGOnbHzzJIF1KDFidV2=	NInrfWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFA6QSd-MUe2PFQxQTl:L3G+
FDC-P1	NH\jWGpHfW6ldHnvckBie3OjeR?=		M1:5UlQ5KGi{cx?=		NIr4[IlKSzVyIE2gNE4xODd2IN88US=>	NFzJO\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1OlY5QSd-MkCxOVY3QDl:L3G+
K562	Ml3UR5l1d3SxeHnjbZR6KGG\|c3H5		MXm3NkBpenN?		NYnB[FhrUUN3MDC9JFEzNjh\|IN88US=>	MnXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUe4O\|coRjJ{MkG3PFc4RC:jPh?=
U937	NVvjWI9wS3m2b4TvfIlkcXS7IHHzd4F6		Mm\KO\|IhcHK\|		NInzdIlKSzVyIE2gNVMvPjNizszN	Mnf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUe4O\|coRjJ{MkG3PFc4RC:jPh?=
Sf21	M3;2dGZ2dmO2aX;uJIF{e2G7		NGT6[YU2KG2rboO=		MlT0TWM2OCB;IEGwJO69VQ>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl4MU[4NUc,OjJ7NkG2PFE9N2F-
Ba/F3	NG\scoRHfW6ldHnvckBie3OjeR?=		MVmxJIhz		MX;Jcohq[mm2aX;uJI9nKEKlcj3BZowhXDNzNVmgcZV1[W62IDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJJBpd3OyaH;yfYxifGWmIGPURXQ2KGyndnXsJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NHHmUYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNFgxPid-MkO2NFA5ODZ:L3G+
Ba/F3	MYjGeY5kfGmxbjDhd5NigQ>?		MVmxJIhz		MkD3TY5pcWKrdHnvckBw\iCEY4KtRYJtKFR\|MUXJJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIITyZY5{\mWldHXkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDv[kBxcG:\|cHjvdplt[XSnZDDDdotNKGyndnXsJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMEiwOkc,OjN4MEC4NFY9N2F-
Ba/F3	M{HJRmZ2dmO2aX;uJIF{e2G7		Mor3NUBpeg>?		NVnhfY41UW6qaXLpeIlwdiCxZjDCZ5IuSWKuIGSzNVVKKG23dHHueEApfW6tbn;3ckBwemmpaX6pJJBpd3OyaH;yfYxifGmxbjD0doFve2[nY4Tl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEC4NFYoRjJ\|NkCwPFA3RC:jPh?=
Sf9	NITld2FHfW6ldHnvckBie3OjeR?=		MYexOUB1dyB{MDDtbY5{		NGKzPWZKSzVyIE2gNVMvOSEQvF2=	NHK4e2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m1OlExOSd-MkO5OVYyODF:L3G+
Sf9	Mo[0SpVv[3Srb36gZZN{[Xl?		MVqyNEBucW6\|		MnXBTWM2OCB;IEK3MlMh\|ryP	NVfFXWsyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OVYyODFpPkKzPVU3OTBzPD;hQi=>
HMC-1.2	NVXnc4xQSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				M3\2R2lEPTBiPTCwMlgzKM7:TR?=	M3POc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC0OFA6Lz5{NUCwOFQxQTxxYU6=
RXF 393NL	NG\OdmpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHfj[nE1KGSjeYO=		NHPFVnpIUTVyIE2gNE4xOjF5IN88US=>	NIPJNHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC3OlE6PSd-MkWwO\|YyQTV:L3G+
LXFA 983L	M3vsO2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4HB[VQh\GG7cx?=		M4niOGdKPTBiPTCwMlA2PjVizszN	NW\JSo5oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|YyQTVpPkK1NFc3OTl3PD;hQi=>
PRXF DU145	M2\HeWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVTObnhqPCCmYYnz		M1T1NWdKPTBiPTCwMlA3OjNizszN	MmjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{[xPVUoRjJ3MEe2NVk2RC:jPh?=
PAXF 1657L	M4W0SGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVXacHBbPCCmYYnz		M1HBUmdKPTBiPTCwMlEzOSEQvF2=	MorlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{[xPVUoRjJ3MEe2NVk2RC:jPh?=
GXF251L	MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3PYfFQh\GG7cx?=		NXX6bYFKT0l3MDC9JFIvOjVizszN	M13zd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEe2NVk2Lz5{NUC3OlE6PTxxYU6=
CXF 1103L	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIfBdY41KGSjeYO=		Mn33S2k2OCB;IESuN\|Yh\|ryP	NIfVR5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC3OlE6PSd-MkWwO\|YyQTV:L3G+
SH-SY5Y	MVPBdI9xfG:\|aYOgZZN{[Xl?	NGHVcZQxNjFidV2=	MWCyOEBpenN?		NI[wNndKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGPIMXN[PVliY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKGi7cH;kbZBtd2mmIHPlcIx{KGG2IECuNUB2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDjfZRw\my3b4LpcYV1enl?	MojQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2Nkm3O\|EoRjJ3NE[5O\|cyRC:jPh?=
ECRF24	NGrU[5BEgXSxdH;4bYNqfHliYYPzZZk>		MoH0O\|IhcHK\|		M1\tUGlEPTBiPTC1Mlch\|ryP	MlfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUWxOVIoRjJ3OEG1NVUzRC:jPh?=
A2780	MVzDfZRwfG:6aXPpeJkh[XO\|YYm=		MWG3NkBpenN?		NEXpbnNKSzVyIE2gPE44KM7:TR?=	NFLkT2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixOVE2Oid-MkW4NVUyPTJ:L3G+
HEK293	NYPqUo9RS3m2b4TvfIlkcXS7IHHzd4F6		NXLNfpBLPzJiaILz		NFv6SlFKSzVyIE2gNVQvOyEQvF2=	M1fBOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEG1NVUzLz5{NUixOVE2OjxxYU6=
MDA-MB-231	NIn6clhEgXSxdH;4bYNqfHliYYPzZZk>		NGS1TlQ4OiCqcoO=		MYPJR\|UxKD1iMD6xO\|gh\|ryP	NFS5WnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVMyPyd-MkW4N\|U{OTd:L3G+
MDA-MB-231	M2j0UGFvfGmrbo\hd4l3\SCjc4PhfS=>	NEe1fXMxNjFidV2=	MmHQNlQhcHK\|		MXzBcpRqcW64YYPpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFAvOSC3TTDh[pRmeiB{NDDodpMh[nlidILhcpN4\WyuIHHzd4F6	NH;mRmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVMyPyd-MkW4N\|U{OTd:L3G+
MDA-MB-231	M{jkd2NmdGxiY4njcIUh[XO\|YYm=	NIe4T\|ExNjNidV2=	M4LyW\|I1KHSxIES4JIhzew>?		MknER4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS\|AwTzFicHjhd4Uh[XRiMD6zJJVOKGGodHXyJFI1KHSxIES4JIhzeyCkeTDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXN?	MlOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{WzNVcoRjJ3OEO1N\|E4RC:jPh?=
MDA-MB-231	NGiySVBHfW6ldHnvckBie3OjeR?=	MWG+NE4xOyC3TR?=	NYrtN4RUOjBiaILz		MXvJcohq[mm2aX;uJI9nKFO{YzDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCIQVugdIhwe3Cqb4L5cIF1cW:wIHH0JF4xNjB\|IIXNJIFnfGW{IEKwJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NFzKSXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVMyPyd-MkW4N\|U{OTd:L3G+
MDA-MB-231	MkL3RY51cW2rZ4LheI9zgSCjc4PhfS=>	MnzDNE4xOyC2bzCwMlMhfU1?	M2DpNFIxKGi{cx?=		M4PRR2FvfGmvaXfyZZRwenliYXP0bZZqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF1KDBwMEOgeI8hOC5\|IIXNJIFnfGW{IEKwJIhzeyCkeTD3c5Vv\CCqZXHsbY5oKGG\|c3H5	M1y1dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N\|E4Lz5{NUizOVMyPzxxYU6=
MDA-MB-231	M{fqbWZ2dmO2aX;uJIF{e2G7	NHnj[nQxNjByMTD0c{AyKHWP	NVqxOJNtOjBiaILz		MV\Jcohq[mm2aX;uJI9nKFO{YzDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjdDCwMlAxOSC2bzCxJJVOKGGodHXyJFIxKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NH7Fc2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVMyPyd-MkW4N\|U{OTd:L3G+
MDA-MB-231	NV71ZlFOSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	MYS+NE4xOSC3TR?=	MWGxNkBl[Xm\|		MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBkd2yxbomg[o9zdWG2aX;uJIF1KD5yLkCxJJVOKGGodHXyJFEzKGSjeYOgZpkh[3K7c4ThcEB3cW:uZYSgd5RicW6rbnetZoF{\WRiYYPzZZk>	M2DuTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N\|E4Lz5{NUizOVMyPzxxYU6=
MDA-MB-231	NIDjTY5CdnSrdIXtc5Ih[XO\|YYm=	M2T6ZVQxKG2pL3vnM4RigQ>?	M3n6VVE5KGSjeYO=		M4rGOWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNieHXuc4dz[W[2ZXSgbY4hW0OLRDDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDC0NEBu\y:tZz;kZZkh[WSvaX7pd5RmemWmIH\vdkAyQCCmYYnzJI1m[XO3cnXkJIV3\XK7IEOg[IF6eyCmdYLpcoch[2:vcH;1coQh\G:\|aX7n	M4joelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N\|E4Lz5{NUizOVMyPzxxYU6=
MDA-MB-231	M1P3e2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M17INlQ5KGi{cx?=		MV7JR\|UxKD1iMT6xNkDPxE1?	MkDTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OUmzN\|IoRjJ3OEm5N\|MzRC:jPh?=
MCF7	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=		M2X4XlQ5KGi{cx?=		NGX2XYxKSzVyIE2gPE4xPSEQvF2=	MkWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OUmzN\|IoRjJ3OEm5N\|MzRC:jPh?=
HCC366	MoDCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mnz6O\|IhcHK\|		NYHCUll4UUN3MDC9JFAvODJ7IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF7MUO2PUc,OjZzOUGzOlk9N2F-
NCI-H2286	MlftRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYr1Z4NWPzJiaILz		MV3JR\|UxKD1iMD6wN\|Ih\|ryP	MmLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOUGzOlkoRjJ4MUmxN\|Y6RC:jPh?=
K562	MVfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3LlfFczKGi{cx?=		NI\lWI1KSzVyIE2gNE4xODFizszN	Ml3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOUWxN\|YoRjJ4MUm1NVM3RC:jPh?=
K562	NVXhOo93S3m2b4TvfIlkcXS7IHHzd4F6				MYrJR\|UxKD1iMD6wPEDPxE1?	NGPObYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2OFUxOyd-Mk[yOlQ2ODN:L3G+
IR-K562	MY\DfZRwfG:6aXPpeJkh[XO\|YYm=				M1n0cGlEPTBiPTCxMlkh\|ryP	NHP5O2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2OFUxOyd-Mk[yOlQ2ODN:L3G+
THP1	M13sc2N6fG:2b4jpZ4l1gSCjc4PhfS=>				M2nyOmlEPTBiPTC2JO69VQ>?	MkL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NkS1NFMoRjJ4Mk[0OVA{RC:jPh?=
HEK293	NGfUOJZEgXSxdH;4bYNqfHliYYPzZZk>				NXK0cJk5S0N3MDC9JFE3KM7:TR?=	MmDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NkS1NFMoRjJ4Mk[0OVA{RC:jPh?=
K562	Mm\0R5l1d3SxeHnjbZR6KGG\|c3H5		M2DtfFQ5KGi{cx?=		MVHJR\|UxKD1iMD60OUDPxE1?	Mn[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2NUG3O\|IoRjJ4NEWxO\|czRC:jPh?=
K562	MoXZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEXrUY04OiCqcoO=		M1jHbmdKPTBiPTCwMlAxODNizszN	NYTXN5pRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NUDXSI5UTnWwY4Tpc44h[XO\|YYm=		M13mdVczKGi{cx?=		MlLSS2k2OCB;IECuNFAxOyEQvF2=	NHfiSYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
KU812	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUC3NkBpenN?		NWjMV3ZET0l3MDC9JFAvODByMzFOwG0>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
MEG01	M{Pj[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1XNSFczKGi{cx?=		M3:2emdKPTBiPTCwMlAxODNizszN	MkDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	M1\2eWZ2dmO2aX;uJIF{e2G7		NV3wNpBYPzJiaILz		NXjTcI1OT0l3MDC9JFAvODBzIN88US=>	MlfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MX;GeY5kfGmxbjDhd5NigQ>?		MXe3NkBpenN?		MVvHTVUxKD1iMD6wNFEh\|ryP	NX[yOIxNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NWnPNI4xTnWwY4Tpc44h[XO\|YYm=		M{f2WVczKGi{cx?=		M1zV[2dKPTBiPTCwMlAxOSEQvF2=	MkLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MoHCSpVv[3Srb36gZZN{[Xl?		Mm\PO\|IhcHK\|		MUjHTVUxKD1iMD6wNFMh\|ryP	NXnEWmhURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	M13OSWZ2dmO2aX;uJIF{e2G7		MnLYO\|IhcHK\|		MljQS2k2OCB;IECuNFA{KM7:TR?=	M2T3XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NH;JeJpHfW6ldHnvckBie3OjeR?=		Ml3EO\|IhcHK\|		MWrHTVUxKD1iMD6wNFMh\|ryP	NWfZSJVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NFqxUZBHfW6ldHnvckBie3OjeR?=		MVy3NkBpenN?		Ml[5S2k2OCB;IECuNFA{KM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NFe0NIRHfW6ldHnvckBie3OjeR?=		NH7Z[ng4OiCqcoO=		NF;ieG1IUTVyIE2gNE4xODRizszN	NXjqfmFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NWHvR3RkTnWwY4Tpc44h[XO\|YYm=		Mnq5O\|IhcHK\|		NIq5UIRIUTVyIE2gNE4xODRizszN	NYTyXpl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NVHRNlJPTnWwY4Tpc44h[XO\|YYm=		MXi3NkBpenN?		NEXFdJpIUTVyIE2gNE4xODVizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	M2rpcGZ2dmO2aX;uJIF{e2G7		M{ntS\|czKGi{cx?=		NYLpPFJ{T0l3MDC9JFAvODB6IN88US=>	NEXXbog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	MXTGeY5kfGmxbjDhd5NigQ>?		NG[wZ2g4OiCqcoO=		MXPHTVUxKD1iMD6wNFgh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	MYPGeY5kfGmxbjDhd5NigQ>?		MYe3NkBpenN?		MnK3S2k2OCB;IECuNFEh\|ryP	M1TLTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NYTBdplbTnWwY4Tpc44h[XO\|YYm=		MmLuO\|IhcHK\|		NX\4NGN2T0l3MDC9JFAvODF2IN88US=>	Ml3XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MWTGeY5kfGmxbjDhd5NigQ>?		MWS3NkBpenN?		MYPHTVUxKD1iMD6wNVQh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NV\jXG17TnWwY4Tpc44h[XO\|YYm=		Ml3IO\|IhcHK\|		MkPmS2k2OCB;IECuNFE4KM7:TR?=	NV;0[JM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NEjFS5RHfW6ldHnvckBie3OjeR?=		MUK3NkBpenN?		NV;WdplxT0l3MDC9JFAvODN7IN88US=>	NInGfnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
CHL	MofDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2LFR\|czKGi{cx?=		NV;vWpB{T0l3MDC9JFAvOjdizszN	NI\zS\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
MOLM14	M12zW2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MnzCO\|IhcHK\|		NVHzcGZGT0l3MDC9JFIvOyEQvF2=	MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	Ml6ySpVv[3Srb36gZZN{[Xl?		NHS4cm84OiCqcoO=		M3PaUmdKPTBiPTCzJO69VQ>?	M4nhS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NEnFVYdHfW6ldHnvckBie3OjeR?=		MXu3NkBpenN?		M2\ZSGdKPTBiPTCzJO69VQ>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
MV4-11	MnGxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUO3NkBpenN?		NUXGcHNXT0l3MDC9JFMvPiEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
HEL	NW\scnJmSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MlfiO\|IhcHK\|		MXnHTVUxKD1iNT6zJO69VQ>?	MnXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	M3rtdWZ2dmO2aX;uJIF{e2G7		NIXYXGw4OiCqcoO=		MX7HTVUxKD1iOT65OEDPxE1?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
KU812	Mk[0SpVv[3Srb36gZZN{[Xl?	NX30NYxJOC5zIIXN	MYGxJIhz		M1XxZ2lvcGmkaYTpc44hd2ZiQlPSM2FDVCCrbjDoeY1idiCNVUixNkBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
KU812	NV2xV45PTnWwY4Tpc44h[XO\|YYm=	MoO2NE4yKHWP	NVnXXHdYOSCqch?=		MVLJcohq[mm2aX;uJI9nKEKFUj;BRmwhcW5iaIXtZY4hU1V6MUKgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gR5JsVCCyaH;zdIhwenmuYYTpc44h[XRiVEKwO{B{cXSnIHH0JFAvOSC3TTDh[pRmeiBzIHjyJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	M1HQZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
MEG01	NIDLcnlHfW6ldHnvckBie3OjeR?=	MkP1NE4yKHWP	MYqxJIhz		M3fDeGlvcGmkaYTpc44hd2ZiQlPSM2FDVCCrbjDoeY1idiCPRVewNUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	NF62[GM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
MEG01	M2\rVWZ2dmO2aX;uJIF{e2G7	MUiwMlEhfU1?	MWWxJIhz		M4fkOmlvcGmkaYTpc44hd2ZiQlPSM2FDVCCrbjDoeY1idiCPRVewNUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
K562	NHqySFdHfW6ldHnvckBie3OjeR?=	M2fMXFAvOSC3TR?=	MUixJIhz		MnT2TY5pcWKrdHnvckBw\iCEQ2KvRWJNKGmwIHj1cYFvKEt3NkKgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gR5JsVCCyaH;zdIhwenmuYYTpc44h[XRiVEKwO{B{cXSnIHH0JFAvOSC3TTDh[pRmeiBzIHjyJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	NGPJfHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
K562	M1rIWmZ2dmO2aX;uJIF{e2G7	NWmwVJc2OC5zIIXN	NIjheI0yKGi{		NEnRXWlKdmirYnn0bY9vKG:oIFLDVk9CSkxiaX6gbJVu[W5iS{W2NkBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
K562	Mn\pR5l1d3SxeHnjbZR6KGG\|c3H5		NUjuSZpKPzJiaILz		NIjGVWhKSzVyIE2gNE4xODB{NTFOwG0>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjhzNEi5NEc,OjZ6MUS4PVA9N2F-
BA/F3	NVL0fm85S3m2b4TvfIlkcXS7IHHzd4F6		NFzDW2k4OiCqcoO=		MYnJR\|UxKD1iMD6wPUDPxE1?	M3LjTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEG0PFkxLz5{NkixOFg6ODxxYU6=
BAF3	MW\GeY5kfGmxbjDhd5NigQ>?		NXnuV\|hjPzJiaILz		MoDNSWM2OCB;IECuNFAxODRizszN	Mk\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMUC4NVAoRjJ5MEGwPFExRC:jPh?=
BAF3	NFS0[4tHfW6ldHnvckBie3OjeR?=		MkTKO\|IhcHK\|		NYG1bGZDTUN3MDC9JFAvODByMESg{txO	M1ricVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEGwPFExLz5{N{CxNFgyODxxYU6=
BxPC3	NFz6dWVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWT5OVJLPzJiaILz		MkezSWM2OCB;IECuNFM{KM7:TR?=	M{jnWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEGwPFExLz5{N{CxNFgyODxxYU6=
MDA-MB-231	MnT4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Ml7YO\|IhcHK\|		NG\Z[3ZGSzVyIE2gNE4xPDRizszN	Mmr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMUC4NVAoRjJ5MEGwPFExRC:jPh?=
Caki2	M4HRO2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXXacGREPzJiaILz		NXLhO5M5TUN3MDC9JFAvODV3IN88US=>	NYjKU\|E3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNVA5OTBpPkK3NFExQDFyPD;hQi=>
NCI-H1975	NXGwPXI1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXe3NkBpenN?		Mn;ZSWM2OCB;IECuNVc{KM7:TR?=	NEDucHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CxNFgyOCd-MkewNVA5OTB:L3G+
PC3	MoOwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M32wUVczKGi{cx?=		MUTFR\|UxKD1iMD6yN\|Ih\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
insect	MnrHSpVv[3Srb36gZZN{[Xl?		NI\KT2szOCCvaX7z		Mn2zTWM2OCB;IECuNFAxPSEQvF2=	MmfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUW4N\|UoRjJ5MUG1PFM2RC:jPh?=
MDA-MB-231	NFTxOFVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3nhOlUh\GG7cx?=		MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDViZHH5d{BjgSCScnXzeI9DdHWnIHHzd4F6	Mn\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUW4N\|UoRjJ5MUG1PFM2RC:jPh?=
MDA-MB-231	MUDGeY5kfGmxbjDhd5NigQ>?	MkS2N{B1dyBzMECgcm0>	MkPuNU42KGi{cx?=		NUL3U5d[UW6qaXLpeIlwdiCxZjDTVmMheGixc4Doc5J6dGG2aX;uJIF1KHS7cn;zbY5mKDRzNjDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFMhfG9iMUCwJI5OKHC{ZXnuZ5Vj[XSnZDDmc5IhOS53IHjyd{Bnd2yub4fl[EBjgSC\|ZYL1cUB{fGmvdXzheIlwdiCob4KgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzNUizOUc,OjdzMUW4N\|U9N2F-
MDA-MB-231	M{\2cGZ2dmO2aX;uJIF{e2G7	MoTWN{B1dyBzMECgcm0>	NIjHenIyNjViaILz		MWLJcohq[mm2aX;uJI9nKE[DSzDwbI9{eGixconsZZRqd25iYYSgeJlzd3OrbnWgPFYyKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiMzD0c{AyODBibl2gdJJmcW6ldXLheIVlKG[xcjCxMlUhcHK\|IH\vcIxwf2WmIHL5JJNmenWvIIP0bY12dGG2aX;uJIZweiBzIHjyJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	M4qydFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG1PFM2Lz5{N{GxOVg{PTxxYU6=
MDA-MB-231	MmXvRY51cW2rZ4LheI9zgSCjc4PhfS=>	M3jETFExKG6P	NUDXcJJjPiCqcoO=		MkPWRY51cW2rZ4LheI9zgSCjY4Tpeol1gSCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuIH3veIltcXS7IHH0JFExKG6PIHH0JFYhcHK\|IHL5JI1q[3Kxc3PvdJkh[mG\|ZXSgd4Nz[XSlaD33c5Vv\CClZXzsJI1q\3KjdHnvckBie3OjeR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzNUizOUc,OjdzMUW4N\|U9N2F-
MCF7	MlX3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	NGLycnYxNjB\|IITvJFMxOCC3TR?=	M3Pz[lUh\GG7cx?=		NH;HXFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGG2IECuNFMhfG9iM{CwJJVOKGGodHXyJFUh\GG7czDifUBRemW\|dH;CcJVmKGG\|c3H5	NG[2OFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxOVg{PSd-MkexNVU5OzV:L3G+
HCT116	MVXDfZRwfG:6aXPpeJkh[XO\|YYm=		MlL3PVYhcHK\|		NHHRVGdKSzVyIE2gOU4zOyEQvF2=	M4D0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1OFY1Lz5{N{G1OVQ3PDxxYU6=
A549	NVSzWpdlS3m2b4TvfIlkcXS7IHHzd4F6		Mn3yPVYhcHK\|		MXPJR\|UxKD1iOD6zO{DPxE1?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF3NUS2OEc,OjdzNUW0OlQ9N2F-
U937	NHPYd49EgXSxdH;4bYNqfHliYYPzZZk>		MYG5OkBpenN?		NXG5UnJ7UUN3MDC9JFExNjJ\|IN88US=>	MknaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzNUW0OlQoRjJ5MUW1OFY1RC:jPh?=
K562	NF7tNZVEgXSxdH;4bYNqfHliYYPzZZk>		M2riR\|k3KGi{cx?=		MW\JR\|UxKD1iMUGuPVUh\|ryP	MoK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzNUW0OlQoRjJ5MUW1OFY1RC:jPh?=
K562	M{XzT2N6fG:2b4jpZ4l1gSCjc4PhfS=>				M1zSW2NEPTBiPTCwMlI2KM7:TR?=	M{XKTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEe0PVE5Lz5{N{S3OFkyQDxxYU6=
K562	M{HaSGFvfGmycn;sbYZmemG2aY\lJIF{e2G7				MmTFS2k2OCB;IECuNFAyKM7:TR?=	NH;CUXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzOVUzPid-Mki0N\|U2OjZ:L3G+
K562	MkPiSpVv[3Srb36gZZN{[Xl?				M2LFfWlEPTBiPTCwMlAxODB4OTFOwG0>	NIjib2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO5OVk4Oyd-MkmzPVU6PzN:L3G+
HL60	M1jK[mZ2dmO2aX;uJIF{e2G7				NVi2VWRFUUN3MDC9JFAvODByMUGg{txO	NFf4[Vk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO5OVk4Oyd-MkmzPVU6PzN:L3G+
KG1a	NYXOUHpQTnWwY4Tpc44h[XO\|YYm=				NFzPclBKSzVyIE2gPE46QCEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN7NUm3N{c,Ojl\|OUW5O\|M9N2F-
B16-BL6	Ml7wSpVv[3Srb36gZZN{[Xl?	NWLC[ok6QC5zMzD1US=>	NHHjdnczPCC2bzC0PEBpenN?		NFzpd49KdmirYnn0bY9vKG:oIHPlcIwhdWmpcnH0bY9vKG:oIH3veZNmKEJzNj3CUFYh[2WubIOgZZQhQC5zMzD1UUBqdmO3YnH0[YQh\m:{IEK0JJRwKDR6IHjyd{BjgSClZXzsJJdwfW6mIIPjdoF1[2hiYYPzZZk>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN7NUm3N{c,Ojl\|OUW5O\|M9N2F-
MCF7	NV3jTGgzTnWwY4Tpc44h[XO\|YYm=	NWrlfno1Py53IIXN	M{DkU\|ExKGSjeYO=		NEPiN2hKdmirYnn0bY9vKG:oIHPvcI9vgSCob4LtZZRqd25iaX6gbJVu[W5iTVPGO{Bk\WyuczDheEA4NjVidV2gbY5kfWKjdHXkJIZweiBzMDDkZZl{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oKGKjc3XkJJBt[XSnIHPsc45qdmdidHXzeC=>	NIj6Oo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO5OVk4Oyd-MkmzPVU6PzN:L3G+
U-2 OS	NITmOmtyUFSVIHHzd4F6				NXXLfoF6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=>	NWnUdIgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	NX\hNZBzeUiWUzDhd5NigQ>?				NGLMXWNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	NF7odYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	NWHBenpPeUiWUzDhd5NigQ>?				NIrzbo9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	NFTIXFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NV\iOVlJeUiWUzDhd5NigQ>?				NETFSFFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	Ml3TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NW\aUpNHeUiWUzDhd5NigQ>?				MnrTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	MoqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	MULxTHRUKGG\|c3H5				MkXvdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOTJiY3XscJM>	M4DnUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	M33L[JFJXFNiYYPzZZk>				NYX2e4VbeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	MoDTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NEXiTXpyUFSVIHHzd4F6				M33OUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	NHfNN\|VyUFSVIHHzd4F6				M4r6PZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	MnPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	NEC2eXlyUFSVIHHzd4F6				MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	NFTDNIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
U-2 OS	M3;Vd5FJXFNiYYPzZZk>				M3P0RpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>?	MnHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	MX;xTHRUKGG\|c3H5				NYP3V4pOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	MWfxTHRUKGG\|c3H5				MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NFzuOGRyUFSVIHHzd4F6				MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	Mn;IdWhVWyCjc4PhfS=>				NXKySGlleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	M4nFcpFJXFNiYYPzZZk>				NGTme4JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDF6IHPlcIx{	NHT3PHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
HEK293	MWXGeY5kfGmxbjDhd5NigQ>?		M3uzNlEhcHJ?		NX3aTG9QU2liPTCwMlAxODVizszN	NIizSY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NVE6Oyd-Mkm5OFEyQTN:L3G+
HEK293	M{PkdGZ2dmO2aX;uJIF{e2G7		NGrzeIMyKGi{		M2TuOGlEPTBiPTCwMlAxPiEQvF2=	NYLobnZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFEyQTNpPkK5PVQyOTl\|PD;hQi=>
Ba/F3	MVrGeY5kfGmxbjDhd5NigQ>?		MVi0PEBpenN?		MlfZS2k2OCB;IECuNFAxOjFizszN	NEXYOHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEGzO\|k5OSd-M{CxN\|c6QDF:L3G+
Ba/F3	MonQSpVv[3Srb36gZZN{[Xl?		M4S1NlQ5KGi{cx?=		M1\ScmdKPTBiPTCwMlAxODJ3IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF\|N{m4NUc,OzBzM{e5PFE9N2F-
Ba/F3	MlexSpVv[3Srb36gZZN{[Xl?		Ml[3OFghcHK\|		NXnsbXFYT0l3MDC9JFAvODByMkmg{txO	NYTsN49bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	NH7keIxHfW6ldHnvckBie3OjeR?=		MUK0PEBpenN?		M{ftT2dKPTBiPTCwMlAxODNizszN	M1LYOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUO3PVgyLz5\|MEGzO\|k5OTxxYU6=
Ba/F3	NUm2bmQ{TnWwY4Tpc44h[XO\|YYm=		NYLSbXJGPDhiaILz		NUnWdI9iT0l3MDC9JFAvODByM{Og{txO	MnHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Ba/F3	NILXeoZHfW6ldHnvckBie3OjeR?=		Mm\ZOFghcHK\|		MXzHTVUxKD1iMD6wNFA1OiEQvF2=	NWXt[4RGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	Ml\kSpVv[3Srb36gZZN{[Xl?		M3rmdVQ5KGi{cx?=		M4rt[GdKPTBiPTCwMlAxODd5IN88US=>	Mn\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Ba/F3	MUXGeY5kfGmxbjDhd5NigQ>?		NGrtb\|E1QCCqcoO=		M2rKUWdKPTBiPTCwMlAxODl6IN88US=>	NUjsTmRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	NEC5WIRHfW6ldHnvckBie3OjeR?=		MXy0PEBpenN?		Mn;DS2k2OCB;IECuNFAyPDRizszN	MkPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Ba/F3	NEDCbFdHfW6ldHnvckBie3OjeR?=		MlfrOFghcHK\|		M1zCeWdKPTBiPTCyMlU3OiEQvF2=	MkTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Vero	M{DQXJFJXFNiYYPzZZk>				MUTW[ZJwKGOnbHzzJJZq[WKrbHn0fUByUFSVIH\vdkBbcWujII\pdpV{KGmwaHnibZRwenN?	NVT3UWxwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{OyNlk2PDVpPkOzNlI6PTR3PD;hQi=>
HepG2	NEPjXIlyUFSVIHHzd4F6				M4PhXGhmeEd{IHPlcIx{KH[rYXLpcIl1gSCzSGTTJIZweiCcaXvhJJZqenW\|IHnubIljcXSxcoO=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OzJ{OUW0OUc,OzN{Mkm1OFU9N2F-
BV-173	NGXidJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTBwMECwNFAxOTB7IN88US=>	M{nndFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
K-562	NES3d4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHS2[olKSzVyPUCuNFAxODByMk[2JO69VQ>?	MmH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
BL-70	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3GTWM2OD1yLkCwNFAxODh{MjFOwG0>	Mn\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
EM-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlexTWM2OD1yLkCwNFAxOTB6IN88US=>	NWr2b3k2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LAMA-84	NX;hUoN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jKXmlEPTB;MD6wNFAxODN{MTFOwG0>	NXXT[3ZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MEG-01	Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1W3R2lEPTB;MD6wNFAxODl6IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
EoL-1-cell	MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoD2TWM2OD1yLkCwNFAyOzFizszN	NF7kfII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CTV-1	NWrjNZNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLaTWM2OD1yLkCwNFA1ODRizszN	M4\DRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
TE-15	M3fXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTBwMEC1PFkh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NOS-1	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fmVmlEPTB;MD6wNFYyOyEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
D-336MG	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3tTWM2OD1yLkCwOlMh\|ryP	M{nmSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LB1047-RCC	NEDrdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkKwTWM2OD1yLkCwPVg6KM7:TR?=	MoDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LB996-RCC	NYL4Zmh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzXZZJqUUN3ME2wMlAxQTlzIN88US=>	M2rH[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SW982	NWPwWY5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTBwMEGxNVUh\|ryP	MnX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TK10	MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTKelZEUUN3ME2wMlAyOTd2IN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
A704	NUT0fG9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTBwMEG0PVEh\|ryP	NUC2UYc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TE-8	M4DL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFH2UJJKSzVyPUCuNFE2PzZizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
DOHH-2	M3HMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTBwMEG3NVkh\|ryP	NY\KT4NyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HOP-62	M13BTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX:3Xog6UUN3ME2wMlAyQDN2IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
TE-12	NGnnTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mle0TWM2OD1yLkCxPFYyKM7:TR?=	NELPVYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KGN	NVzzTIRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHXbIVKSzVyPUCuNFE6PDJizszN	M2jHclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H1648	Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkP4TWM2OD1yLkCyNFEyKM7:TR?=	NILnRWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
OS-RC-2	M2nuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjWWWZKSzVyPUCuNFIxOyEQvF2=	NVnqOW9kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
GB-1	NH36RXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;lTWM2OD1yLkCyNVU4KM7:TR?=	NYTaeZRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RXF393	NFLmSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3ySopKSzVyPUCuNFI{PTdizszN	MnX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LC-2-ad	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7aTWM2OD1yLkCyOVg3KM7:TR?=	MnPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KS-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofxTWM2OD1yLkCyO\|Mh\|ryP	NVTTZ4VqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
ETK-1	NFSwXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXWyNFBUUUN3ME2wMlAzQDN{IN88US=>	NYK3V\|JTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SW954	MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1X0emlEPTB;MD6wNlkzPyEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
Becker	NV;BNop7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjFb5pKSzVyPUCuNFMxODNizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MZ1-PC	NGLaNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTBwMEOxNVkh\|ryP	NYjIN\|RxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
ES6	NEPxbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTBwMEOxPVMh\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KURAMOCHI	M4PSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHnWmpKSzVyPUCuNFM1QDdizszN	NFW0PW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CGTH-W-1	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjtUW1KSzVyPUCuNFM2PDhizszN	M2jsTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
VA-ES-BJ	NWrDbnE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTBwMEO5NFIh\|ryP	M2Cxe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LXF-289	NEfSSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTBwMEO5OVYh\|ryP	MnPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MPP-89	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmL4TWM2OD1yLkC0NFQ6KM7:TR?=	NGS5dmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SW872	NEHnWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LqN2lEPTB;MD6wOFE3OSEQvF2=	MkS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SNB75	NITxRZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\hTWM2OD1yLkC0OFM2KM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
PSN1	NF;Kb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTBwMES0O\|Qh\|ryP	NX3qU2xCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LB831-BLC	NY\FfI1ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTBwMES2NFkh\|ryP	Mo\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MFH-ino	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHVeWw5UUN3ME2wMlA1PzJ2IN88US=>	MmnxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TGBC24TKB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYD5R\|ZvUUN3ME2wMlA1PzZzIN88US=>	MkD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
A388	M4DnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHmxeYZKSzVyPUCuNFUxQTVizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
BB30-HNC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHRNW9DUUN3ME2wMlA2PDN5IN88US=>	NWjldlVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
GI-ME-N	MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\0cGlEPTB;MD6wOlEyQCEQvF2=	M4fG[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
TGBC1TKB	M1KyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTBwME[xOlQh\|ryP	NVjTUodDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TE-10	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\NbmlKSzVyPUCuNFY{PTdizszN	M3ixN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
A498	NVzRSmJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHDT4ZKSzVyPUCuNFczQDRizszN	MmixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TE-11	NVX6fJJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTBwMEe4OVgh\|ryP	M{XnbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
BB65-RCC	NYDuUYJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWq3WoJ7UUN3ME2wMlA5OjJ5IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
C2BBe1	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUSzUnl4UUN3ME2wMlA5OzB6IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H747	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TtOGlEPTB;MD6wPFM3OiEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
IST-MES1	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIribZNKSzVyPUCuNFg2PTJizszN	MlrEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KALS-1	NVe2fZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDtU3NJUUN3ME2wMlA6PDlizszN	NFznPXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
GCIY	NEXReoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTBwMEm2OVYh\|ryP	NFjIXng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
RL95-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fKXmlEPTB;MD6xNFM5KM7:TR?=	MmS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TE-1	MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTBwMUC1OEDPxE1?	M4PyNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H1355	NIizU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;IToVJUUN3ME2wMlEyODJ6IN88US=>	NWLZe5ozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SW962	M{HKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DxdGlEPTB;MD6xNVI6OiEQvF2=	NV7kU45NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KLE	NIPTRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTBwMUGzNVch\|ryP	M1;DXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MC116	M3vqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDtUWs4UUN3ME2wMlEyPDFizszN	NEHRdGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NMC-G1	M3fBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTBwMUG2NFYh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KU812	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTKTWM2OD1yLkGxPFg{KM7:TR?=	NHu4Rmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
COLO-829	NVHNeZBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTBwMUKyNVMh\|ryP	M13tSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NTERA-S-cl-D1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fwOmlEPTB;MD6xNlI5OyEQvF2=	MoDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
IST-MEL1	NIHYRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\RTWM2OD1yLkGzOFUh\|ryP	Ml\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MLMA	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGW0cHdKSzVyPUCuNVQxOzJizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LS-123	NIrTfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;ycmlEPTB;MD6xOFA3PCEQvF2=	MoP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LB2518-MEL	MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkezTWM2OD1yLkG0NVYzKM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NB69	NX3SbIlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTBwMUS0N\|Yh\|ryP	NWj1NWRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
8-MG-BA	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLYTWM2OD1yLkG1OFU5KM7:TR?=	NHr3W209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
K5	NXrjcJp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnrNmlKSzVyPUCuNVY1QDlizszN	MnfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KINGS-1	M3nKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXxVnM1UUN3ME2wMlE3PjZ4IN88US=>	M{W4U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SF268	M1H1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV32Rld6UUN3ME2wMlE4PDB2IN88US=>	M120U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
PF-382	NHraeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTBwMUe2O\|gh\|ryP	M4LvbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SH-4	NFzhNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TSTGlEPTB;MD6xPFQyOyEQvF2=	MonsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NALM-6	NGHtUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTBwMUmyPVUh\|ryP	NVTMSoo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
CP66-MEL	NGn3bVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfESIpKSzVyPUCuNVk2OzFizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
697	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vKcWlEPTB;MD6xPVk5PyEQvF2=	NGjUZpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CP67-MEL	M4LvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4H5emlEPTB;MD6yNFQ5QCEQvF2=	M1iwWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
DSH1	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fwOWlEPTB;MD6yOFAxOSEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HCE-4	NUnBUYdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjoZ\|M2UUN3ME2wMlI3PDN7IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MZ2-MEL	Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTBwMki1N\|ch\|ryP	NVjOb2J6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
BL-41	MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTBwMkmxNlMh\|ryP	MlPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HUTU-80	M{\TbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7HTWM2OD1yLkOxOFIh\|ryP	NUTrZXE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LOXIMVI	MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDSeIlKSzVyPUCuN\|E2ODNizszN	NV;JfI03RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
no-10	NHnJSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jPPWlEPTB;MD6zNVk{OSEQvF2=	M1TJXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
KARPAS-422	MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXT3PYllUUN3ME2wMlM{QTl5IN88US=>	Mnu2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SW684	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHTRWp3UUN3ME2wMlM1QThizszN	NVOwRVR3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SF126	NV7CSolLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1O0[GlEPTB;MD6zOVQyKM7:TR?=	NVXzbJhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
D-263MG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTBwM{[yNlQh\|ryP	MkLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
OVCAR-4	M2rkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwM{e0N\|Mh\|ryP	M3TkeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
BB49-HNC	NFjwZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\ZTWM2OD1yLkO4OVk6KM7:TR?=	M2XxW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
ONS-76	MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLLbG1xUUN3ME2wMlQzQTVzIN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MZ7-mel	NFTwV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGi1TnlKSzVyPUCuOFc6OTFizszN	M13udVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
RCC10RGB	MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWr4VHM5UUN3ME2wMlQ6OTFizszN	NHjsSXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BOKU	NW[1S\|FST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTBwNEmxN\|Mh\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
no-11	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jpWWlEPTB;MD61NFIzQCEQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
IST-SL2	M362[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jKdmlEPTB;MD61NFMxOiEQvF2=	NWGzRlFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RKO	NUDJeXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mki1TWM2OD1yLkWyPVY3KM7:TR?=	MmjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HT-144	MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDWS\|AxUUN3ME2wMlU{PjB7IN88US=>	M3jEU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H446	NX7k[pNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnSTWM2OD1yLk[yO\|Yh\|ryP	NEDXSpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
QIMR-WIL	NIfxbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHlTWM2OD1yLkewOlI6KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MHH-PREB-1	NXXyflllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHYNoZiUUN3ME2wMlc1PDZ7IN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
EW-16	MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mom5TWM2OD1yLke2NVc5KM7:TR?=	M1\YVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EW-24	M1qz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjyTWM2OD1yLke4NVY2KM7:TR?=	NWO5NGdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LB373-MEL-D	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1n3SmlEPTB;MD64NlUxQCEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
TE-9	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XoVmlEPTB;MD64O\|U{OiEQvF2=	MnnVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
A3-KAW	NHjOXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\4S4VsUUN3ME2wMlk5PDV{IN88US=>	Mn2wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
A101D	NHnuOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\4b3VnUUN3ME2xMlA{ODR\|IN88US=>	MkXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
OCUB-M	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTFwMES0NVIh\|ryP	M3L5RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
ES4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7BTWM2OD1zLkC1NVQ2KM7:TR?=	MlzYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TE-6	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jycmlEPTB;MT6yNVIzPiEQvF2=	NIX6TlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
D-502MG	NY\WXFFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXuV5FKSzVyPUGuNlM{PzZizszN	NVTlc24yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KNS-42	NXe1flZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;mc3B5UUN3ME2xMlI1PDF{IN88US=>	MoHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SNU-C2B	M3jVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPOTWM2OD1zLkOwOVg6KM7:TR?=	NYrLVlA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H1838	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfYe4FKSzVyPUGuN\|A4OzNizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NKM-1	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTFwM{C4OVkh\|ryP	M4eyV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GI-1	NGm0bnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUG4eHVtUUN3ME2xMlM3OjJizszN	Mn;6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NB5	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzxW4x[UUN3ME2xMlM6QDJ5IN88US=>	MmLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
CAS-1	M4H5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjBfZpDUUN3ME2xMlQxQTl{IN88US=>	MojNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HCE-T	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLhTWM2OD1zLkW2O\|E1KM7:TR?=	NX3SR4E{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SBC-1	NXr1RZVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlf1TWM2OD1zLkW3PVg1KM7:TR?=	MkntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
JiyoyeP-2003	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTyWJhKUUN3ME2xMlc{PDZ4IN88US=>	NY\QTmd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TE-5	NEDhc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PtfmlEPTB;MT63PVE{QSEQvF2=	Mn[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
CAN	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnXZok2UUN3ME2xMlgzOjV{IN88US=>	Mn7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SK-UT-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXFTWM2OD1{LkG2Olk{KM7:TR?=	NYTqXm1jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
JVM-2	NYftN\|FvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTJwM{[yPFQh\|ryP	NGHSOWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LB771-HNC	NGro[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTDeGVKSzVyPUKuOVc2PTFizszN	M{O2UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCCIT	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXTTWM2OD1{Lki2OlE3KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H2126	MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIizO2lKSzVyPUKuPFc2PTJizszN	Ml7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
Calu-6	NYXtXmtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGm0TJNKSzVyPUOuNFU4PDFizszN	Mon5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SK-LMS-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTNwMUG4PFYh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
ARH-77	M{fQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPQco5KSzVyPUOuOFY6OTVizszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NB17	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTNwNkO4OFch\|ryP	NHKwb3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
A253	MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nyd2lEPTB;Mz63N\|I1PiEQvF2=	NWj3S4J3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
OPM-2	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTRwMke2PFUh\|ryP	MnWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MV-4-11	NWWw[3dXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DCd2lEPTB;ND6zOlQ2PCEQvF2=	MkfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SR	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmqxTWM2OD12LkS5PVU1KM7:TR?=	M3;mO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
KG-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXpSIc{UUN3ME20MlYxQDR3IN88US=>	NICyNmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
OCI-AML2	NX[0ZndzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTVwOE[xOVQh\|ryP	NGexb289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
D-247MG	NF;EUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3X6S2lEPTB;Nj6xNlUyQSEQvF2=	M2\Xd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
DJM-1	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7WbHZWUUN3ME22MlQ5PTV6IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
RPMI-6666	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvVTFEzUUN3ME23MlI4ODZ5IN88US=>	NHywSFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KARPAS-45	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPDZplOUUN3ME23MlUyPjdzIN88US=>	NX\6WFBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LP-1	NXzpNWNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTdwNUS3PFIh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
RS4-11	M4XZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTdwNkW3PFch\|ryP	NUXpV3hCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
DU-4475	M4TVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRThwMkG2OVIh\|ryP	NHW0O4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MONO-MAC-6	M4HzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRThwMkewOlYh\|ryP	MoLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-SNU-16	MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLoTWM2OD16LkW2NVI5KM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SJSA-1	M3rzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRThwN{K4NFUh\|ryP	NXj0RZJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MMAC-SF	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn2yTWM2OD16Lke5N\|A4KM7:TR?=	NYH2NXFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SK-NEP-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfu[nhGUUN3ME24Mlg6OTV3IN88US=>	NEC4XZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NX\LNYx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\sWGlEPTB;OD65OlUzQSEQvF2=	MmT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SKM-1	Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\vRpA3UUN3ME25MlAyPzN2IN88US=>	NVTEc4VCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LB2241-RCC	NVfnNmdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjQN4hYUUN3ME25MlAzODF{IN88US=>	M3P2T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SIG-M5	NHf3UGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTlwMEK0PVMh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
EVSA-T	NX\CTYR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXGxcIoxUUN3ME25MlI4Pzl\|IN88US=>	NGjEcnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
GT3TKB	M3;VUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkmzTWM2OD17LkO1OVQ3KM7:TR?=	M1y4S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NB6	NXz2OGNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrvWI52UUN3ME25MlkzOjV7IN88US=>	M2H0cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EHEB	M3XyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfHTWM2OD1zMD6wOlU3KM7:TR?=	NHXtdZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
HEL	M3LiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPpUVNGUUN3ME2xNE41Pzd4IN88US=>	MnnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ALL-PO	MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTFyLke5N\|gh\|ryP	NXPtPYRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TGW	NIPPPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlOyTWM2OD1zMT6yPFI5KM7:TR?=	MnXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
BC-3	M1O5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTF{LkGxN\|gh\|ryP	NGHNe4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
IA-LM	NGLi[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDRZZNsUUN3ME2xNk41PDR3IN88US=>	NYDlNndmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
UACC-257	NH3mbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrhUXVpUUN3ME2xNk46OTl6IN88US=>	NHX6UXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KP-N-YS	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XubGlEPTB;MUKuPVI5OyEQvF2=	M2DCN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
Raji	NX\jOXRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDQWFdKSzVyPUGzMlc1QTdizszN	NYnZb3B3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SF539	MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvJXnlKSzVyPUGzMlg2PTdizszN	MmnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
DMS-153	NIjodm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7t[lNKSzVyPUG0MlAxOjhizszN	MlzyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
L-540	NEXL[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jlRWlEPTB;MUWuNFY4OiEQvF2=	NXXONFRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MN-60	M1zJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzqUpVKSzVyPUG1MlE6PzlizszN	NVv2TIFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RPMI-8866	M{L2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlW5TWM2OD1zNz60OFU1KM7:TR?=	NIL4flk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H510A	MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTsU41LUUN3ME2xPU4{QTd\|IN88US=>	NE\FN3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NB13	NYTYV2RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTF7LkS4O\|ch\|ryP	M2j1dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
HAL-01	M4G1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjCWHZRUUN3ME2xPU44PTR\|IN88US=>	NXjxR2N{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H720	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDnTWM2OD1{MD6yO\|M{KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
REH	NEWzSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTJyLk[zOVch\|ryP	NEjFXoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KNS-81-FD	NXWxPWpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfaOodKSzVyPUKzMlE1PiEQvF2=	NWfab5Y4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HC-1	MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3FWIFKSzVyPUK0MlU2PTFizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H2141	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTJ2Lke3OVQh\|ryP	NYn4OWJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MOLT-4	M3X1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn[xTWM2OD1{Nj62O\|U{KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
OMC-1	M{fZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfhZ5RKSzVyPUK3MlE1OjJizszN	NFjkVFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LC-1F	M3zSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHe3U\|ZKSzVyPUK3MlMzPDVizszN	NXnjVlRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H1304	M2nwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjVTWM2OD1{OD6xOlI5KM7:TR?=	NH7yOGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BC-1	NH\tbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJ6Lk[1NUDPxE1?	MnrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-H64	NUnJW29UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTsTWM2OD1{OT62NlU{KM7:TR?=	M3H2b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MOLT-16	NFnpTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHL1WXRKSzVyPUK5MlYzQTJizszN	NXXZWYl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
U-87-MG	NXTUeXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLvW25KSzVyPUOwMlc3PiEQvF2=	NHvDZXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
GAK	NY[5TXZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvRfmJKSzVyPUOxMlI3QDZizszN	NVjMZlEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
ES8	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTN{LkGyOVIh\|ryP	MlrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HCC1599	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVqw[\|lvUUN3ME2zNk4{OzJ3IN88US=>	NEPM[\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
EB-3	NV22eHo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVOxfIpqUUN3ME2zOE4{OTF5IN88US=>	MlrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HCC1187	NIfzfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mme4TWM2OD1\|NT64NFUzKM7:TR?=	NUTaeWdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SK-PN-DW	NG[xelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPVWXFKSzVyPUO2MlE6PDNizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
JVM-3	NFjveXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfYVoJvUUN3ME2zO{4zOzN6IN88US=>	M1jk[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
HCC2157	M1jRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXjbIJQUUN3ME2zO{46QTR4IN88US=>	MoLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
A4-Fuk	M3PXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HxR2lEPTB;M{iuNVAxQSEQvF2=	NHnSdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
COR-L279	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWS5e\|REUUN3ME20NE4zQDVzIN88US=>	NVzEdZdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
DEL	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPETWM2OD12MT65NFg3KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H1395	NIrRd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\jeoxKSzVyPUSyMlAyPjNizszN	NUXFOYEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MHH-NB-11	NVHTbJRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP4TWM2OD12Mz6wPFE5KM7:TR?=	NVHydlNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H2107	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7rTWM2OD12Mz60PFQ3KM7:TR?=	M3nZXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NEC8	NFLWTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnTSHBUUUN3ME20OE4{OzZizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
COLO-684	NF\1NIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTR4LkKyOVgh\|ryP	MoHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LS-411N	M3TLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTR6LkS3OFgh\|ryP	NWPhVGtbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	- Collapse Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- Collapse

Solubility (25°C)

In vitro	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib SDF

Molecular Weight	488.01
Formula	C₂₂H₂₆ClN₇O₂S
CAS No.	302962-49-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	BMS-354825
Smiles	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Recruiting	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	February 14 2020	Phase 1\|Phase 2
NCT04155411	Recruiting	Drug: Dasatinib	Dasatinib\|BCR-ABL\|Chronic Myeloid Leukemia	Shenzhen Second People''s Hospital	December 1 2019	Phase 4
NCT04115059	Recruiting	Drug: Dasatinib	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 4 2019	Phase 1
NCT03318770	Not yet recruiting	Drug: Dasatinib and blinatumomab	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Drug: Dasatinib	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Pan Src Inhibitor

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
KX2-391 (Tirbanibulin)

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 (AGL 1872, EI 275) is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 (KIN001-112, KIN112) is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib